Natural Capsules Q1 FY27: Revenue ₹48.71 Cr, Net loss ₹5.74 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹49Cr
- +7.8% YoY
- −16.7% QoQ
- Net profit
- −₹6Cr
- Q1 FY26: −₹6 Cr
- Margin
- 2.3%
- +1.6 pp YoY
- 0 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Natural Capsules Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q1FY27: ₹48.71 crore - Year-on-year (Y-o-Y) revenue growth: +8% - Quarterly EBITDA: ₹1.12 crore, up 251% year-on-year (YoY), down 16% quarter-on-quarter (QoQ) - EBITDA Margin: 2.30%, up 159 basis points YoY, up 2 basis points QoQ - Profit After Tax (PAT): Loss of ₹5.74 crore, a 3% improvement YoY, 15% worse QoQ - Revenue from Operations: ₹48.71 crore, up 8% YoY, down 17% QoQ Margin Outlook (Management Commentary): - Capsules business delivered healthy margins with successful cost pass-throughs supporting margin preservation.
From Natural Capsules Ltd's Q1 FY27 earnings-call transcript · updated 1 Oct 2026.
Revenue & Sales Performance
- Revenue from Operations for Q1FY27: ₹48.71 crore
- Year-on-year (Y-o-Y) revenue growth: +8%
- EBITDA for Q1FY27: ₹1.12 crore, up 251% Y-o-Y
- Management outlook: Confident of sustained performance and profitably in the capsules business through the financial year and sustained demand trends into Q2FY27.
- Temporary conversion of HPMC lines to gelatin lines to optimize capacity and protect profitability due to erratic US market demand.
2 more points from Natural Capsules Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Natural Capsules Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Installed capsules manufacturing capacity as at FY26 stands at 20.25 billion capsules per annum (BCPA), increased from 19.50 BCPA by commissioning one new HPMC line machine in FY26 (Page 12, 18).
- Plans to explore setting up capsules manufacturing facilities in foreign/domestic markets to ensure quick supply (Page 27).
- Investment in technology and manufacturing processes to attain efficiencies and competitive advantage noted (Page 28).
2 more points from Natural Capsules Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Natural Capsules Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Natural Capsules Ltd said on order book & pipeline — free account, 30 seconds.
Natural Capsules Ltd — Quarterly revenue & net profit
Natural Capsules Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 |
|---|---|
| Revenue | 49 |
| Operating profit (EBITDA) | 1 |
| Operating margin | 2.3% |
| Profit before tax | -6 |
| Net profit (PAT) | -6 |
| EPS (₹) | -5.55 |
Source: Natural Capsules Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹51 Cr, net loss ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Natural Capsules's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Aptus Pharma (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Natural Capsules Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natural Capsules Ltd Q1 FY27 results?
Revenue from Operations for Q1FY27: ₹48.71 crore - Year-on-year (Y-o-Y) revenue growth: +8% - Quarterly EBITDA: ₹1.12 crore, up 251% year-on-year (YoY), down 16% quarter-on-quarter (QoQ) - EBITDA Margin: 2.30%, up 159 basis points YoY, up 2 basis points QoQ - Profit After Tax (PAT): Loss of ₹5.74 crore, a 3% improvement YoY, 15% worse QoQ - Revenue from Operations: ₹48.71 crore, up 8% YoY, down 17% QoQ Margin Outlook (Management Commentary): - Capsules business delivered healthy margins with successful cost pass-throughs supporting margin preservation.
What is Natural Capsules Ltd share price analysis?
Natural Capsules Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹197 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natural Capsules Ltd planning capital expenditure?
Installed capsules manufacturing capacity as at FY26 stands at 20.25 billion capsules per annum (BCPA), increased from 19.50 BCPA by commissioning one new HPMC line machine in FY26 (Page 12, 18).
Keep Natural Capsules Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
